R&D channel feed

In­hibikase shelves Parkin­son’s as­set af­ter Phase 2 flop

3 months ago

Ex­clu­sive: Fer­til­i­ty start­up to be­gin Phase 3 study of stem cell ther­a­py for IVF

3 months ago
FDA+

Ahead of earn­ings, Lil­ly culls mid-stage drug for heart fail­ure and chron­ic kid­ney dis­ease

3 months ago
Pharma

Leap Ther­a­peu­tics treks to­ward piv­otal study in col­orec­tal can­cer, drops gas­tric can­cer

3 months ago

ITM aims to com­pete with No­var­tis af­ter Phase 3 ra­dio­phar­ma win

3 months ago

Sarep­ta shares two-year DMD study da­ta that could in­form Eu­ro­pean ap­proval de­ci­sion

3 months ago
Pharma
FDA+

Bris­tol My­ers shares IO com­bo da­ta in col­orec­tal can­cer; Pfiz­er still wait­ing on Braftovi reg­i­men sur­vival fig­ures

3 months ago
Pharma

Veru's drug lessens loss of lean mass in pa­tients tak­ing We­govy

3 months ago

Up­dat­ed: Akero re­deems its fail­ure in se­vere MASH with longer-term da­ta

3 months ago

Agenus con­tin­ues part­ner­ship talks for an­ti-CT­LA-4 com­bo with new Phase 2 da­ta

3 months ago
Deals

Mer­ck and Ei­sai re­veal late-stage fail for Keytru­da and Lenvi­ma in gas­troe­sophageal can­cer

3 months ago
Pharma

The cru­cial obe­si­ty da­ta to watch for this year

3 months ago

As­traZeneca al­lo­cates $570M for Cana­di­an ex­pan­sion, looks to add 700 new jobs

3 months ago
Pharma

No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al

3 months ago
China

ALX On­col­o­gy to make case for ac­cel­er­at­ed ap­proval with new evor­pacept da­ta in gas­tric can­cer

3 months ago

An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?

3 months ago

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

3 months ago
China
Cell/Gene Tx

Xilio re­ports hand­ful of re­spons­es for com­bo in col­orec­tal can­cer

3 months ago

Tris Phar­ma de­clares Phase 3 win for 'o­pi­oid-like' painkiller. Can it sell?

3 months ago

In­hi­brx’s ear­ly col­orec­tal can­cer da­ta cloud­ed by pa­tient death

3 months ago

'No mir­a­cles': What Re­gen­eron's George Yan­copou­los re­al­ly thinks of AI

3 months ago
AI

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

3 months ago

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

3 months ago
China
In Focus

With sup­port from NFL own­er Jef­frey Lurie, Ice­landic biotech clos­es Se­ries A for oral Alzheimer's drug

3 months ago
First page Previous page 891011121314 Next page Last page
A service from the Financial Times